The portal O Petróleo highlighted that Sanepar's preferred shares, SAPR4, are already more than 30% below their peak, drawing attention to the company's R$ 13 billion investment plan. That plan, however, was approved back in December 2025. The stock's decline stems primarily from Paraná's utility regulator, which stripped shareholders of funds from a court-ordered debt (precatório) that the market had expected to receive as an extraordinary dividend.
Why Is SAPR4 Falling?
There are three main reasons, in order of weight. First, Agepar, Sanepar's regulatory agency, decided that the entire court-ordered debt payout should go toward consumer tariff relief. Second, that decision turned into an accounting loss in the second quarter. Third, the company has entered a capital expenditure cycle that consumes nearly all its cash generation. In terms of price, the stock moved from a 12-month high of R$ 9.23 (according to our database; other sites record R$ 9.08) down to R$ 6.28 by the end of October. That represents a 32% drop by our calculation, or 31% using the R$ 9.23 peak.
None of these three reasons are new. Investors looking for a sudden material fact behind the week's headlines will not find one: Brazil's securities regulator, the CVM, records nothing beyond the results of the SAINP auction on October 28. The more useful question is: what is already priced in, and what could still worsen? To answer that, we need to retrace the timeline.
The turning point was the ruling on the court-ordered debt. In its appeal, Sanepar asked to maintain the split established in 2024: 75% of the amount to reduce tariffs and 25% retained by the company. With Agepar's decision, half of the funds go to non-refundable investments and the other half to water bill discounts. Out of the 25% share of roughly R$ 3.9 billion, the portion the company gave up amounts to close to R$ 975 million by our calculation. That was intended to be the cushion for an extraordinary payout: CEO Wilson Bley told Money Times that the decision was critical for distributing extraordinary dividends. The company stated it will continue pursuing appropriate legal measures, meaning the dispute has moved out of the administrative sphere but is far from over.
Yet why did this appear as a loss if the underlying operations are performing well? This is where financial statements can mislead investors who look only at the bottom line.
Is Sanepar Actually Generating Losses?
Not operationally. The ruling forced Sanepar to recognize an additional R$ 952.7 million in regulatory liabilities during the quarter, a one-time provision. Without this effect, Q2 2026 earnings would have grown. The real issue for income-focused investors lies at the bottom of the table.
| Indicator | 2025 | 2026 |
|---|---|---|
| Q1 Net Income | R$ 1,208.0 million | R$ 352.7 million |
| Q2 Net Income | R$ 263.8 million | −R$ 505.2 million |
| Q2 Adjusted Net Income | R$ 331.5 million* | R$ 447.5 million |
| Net Debt (June) | R$ 5.30 billion | R$ 2.59 billion |
| First-Half JCP and Dividends | R$ 420.4 million | Zero |
*Our estimate: 2026 adjusted earnings grew 35% over the previous year, according to Genial (R$ 447.5 million ÷ 1.35). The remaining figures are from Sanepar and Genial.
In short, Genial calculates that excluding non-recurring items, adjusted EBITDA reached R$ 799.9 million (+15.1%) and adjusted net income reached R$ 447.5 million (+35.0%). Net debt was cut in half. The core business is therefore healthier than it was last year. What vanished is the payout: on the earnings release's Value Added Statement, the first-half interest on equity (JCP) line went from R$ 420.4 million to zero. As a result, our database shows only R$ 0.11 per share paid over the last 12 months, representing a dividend yield of 1.74%. In 2025, the two ex-dividend dates totaled roughly R$ 0.40.
If operations improved, why aren't dividends returning quickly? The answer lies in the R$ 13 billion investment plan, which forms the core of the headline.
Does the R$ 13 Billion Plan Threaten Dividends?
It did not trigger the stock drop on its own, but it is the main obstacle preventing dividends from returning to their previous levels. Moody's Local stated in a March report that the high level of capital expenditures will likely continue weighing on free cash flow. The calculation below illustrates this scale, comparing projected annual disbursements with 12-month EBITDA, which we estimate at R$ 2.69 billion (revenue of R$ 7.54 billion × a margin of 35.74%, both from our database).
In 2029 and 2030, projected investments will exceed current EBITDA. Before then, they will consume nearly all of it. Added to this is the SAINP lease agreement: R$ 9.03 million per month, or R$ 108 million per year, representing about 4% of that EBITDA for more than 20 years, as we detailed in our analysis of the SAINP auction. A financial cushion exists: the company held R$ 5.6 billion in cash and short-term investments at the end of 2025, and debt stands at approximately 1x EBITDA. However, that cash cushion is earmarked for capital projects rather than extra payouts. When almost all EBITDA goes toward construction, little is left for semiannual JCP distributions.
What This Means for Shareholders, and Key Questions Ahead
For investors who bought shares primarily anticipating the court-ordered debt payout, the thesis ended in August, and the market price already reflects that. For those who bought based on operations, the core thesis remains intact: rising revenue, higher adjusted margins, and low debt. What has changed is the investment horizon, which now depends on tariff adjustments and operational growth rather than an extraordinary windfall. Our valuation model from October 29 estimates fair value at R$ 5.82, within a range of R$ 4.09 to R$ 6.68, and maintains a "hold" rating. Even after the decline, the stock sits in the upper half of that range rather than below it. While inexpensive on a price-to-book basis at 0.81x, it is not cheap based on the free cash flow remaining for shareholders.
How many times per year does SAPR4 pay dividends? Historically, twice a year via semiannual interest on equity (JCP), with ex-dividend dates near July 1 and December 31. The ex-date for July 2026 did not occur. The next payout window is late December.
SAPR4 or SAPR11? SAPR4 represents preferred shares: they carry no voting rights but have priority in dividend distributions. The SAPR11 unit bundles common and preferred shares into a single security. Regulatory risk applies equally to both, meaning the choice comes down to liquidity and relative pricing rather than the underlying investment thesis.
Is the decline isolated to Sanepar? Partly, no. In October, we showed that a 5.77% drop without a new corporate catalyst affected the entire sanitation sector. Days earlier, a 6.60% rally also occurred without news, highlighting the same pattern: the stock swings sharply with sector sentiment. The underlying trend, however, is company-specific and driven by the regulator.
What to Monitor Following the November 12 Earnings Report
Accounting vs. Adjusted Earnings in Q3 2026: If the gap between the two narrows back toward the Q2 adjusted net income of R$ 447.5 million without new regulatory provisions, the impact of the court debt is behind us. A new write-down would reintroduce risk.
Signals Regarding Second-Semester JCP: An announcement targeting a December ex-dividend date, even if modest, would close the "year without payouts." Silence through December would confirm a yield near 2%.
Executed Capex vs. the R$ 2.6 Billion Projected for 2026: Spending significantly ahead of schedule would pressure cash flow prematurely. Net debt exceeding 1.5x EBITDA would serve as an early warning threshold.
Agepar Public Consultation No. 006/2026: This consultation establishes the new tariff adjustment methodology. An adjustment below inflation would represent the second regulatory blow of the year.
Price vs. Our Valuation Range: Below R$ 5.82, the stock begins to offer a margin of safety according to our model. Above R$ 6.68, the price drop would have reversed without fundamental justification.
In summary: SAPR4 is not falling due to a sudden new event, and the R$ 13 billion plan dates back to December 2025. The decline is the price of three factors: the court-ordered debt redirected to water tariff relief, the accounting loss that resulted, and a construction cycle that leaves minimal cash for shareholders. Operations have improved, but dividends will not return while capital projects consume nearly all EBITDA. Verdict maintained: hold. This is neither the time to sell in panic nor to buy under the assumption that the drop has made the stock cheap. The November 12 earnings report will be the next test.